Pierre Fabre v. Annora Pharma: Propranolol Hemangioma Patents Upheld by Consent Judgment
Pierre Fabre Medicament SAS, Université de Bordeaux, and affiliated plaintiffs filed an ANDA patent infringement action in Delaware against Annora Pharma over two Orange Book-listed patents protecting propranolol for hemangioma treatment. The case resolved after 754 days with a consent judgment affirming infringement, validity, and a permanent injunction blocking Annora’s generic entry.
ANDA showdown: beta-blocker hemangioma patents survive generic challenge
On 2 November 2022, Pierre Fabre Medicament SAS, Université de Bordeaux, Centre Hospitalier Universitaire de Bordeaux, and Pierre Fabre Pharmaceuticals, Inc. collectively filed suit in the District of Delaware against Annora Pharma Private Ltd., an Indian generic pharmaceutical company. The action centred on Annora’s ANDA No. 217567 seeking approval to market a generic propranolol product, which plaintiffs alleged would infringe Orange Book-listed patents US8987262B2 and US8338489B2 covering the use of propranolol (a beta-blocker) for treating infantile hemangiomas.
The action concluded on 25 November 2024 via a stipulated consent judgment entered by Judge Jennifer L. Hall. Crucially, the judgment explicitly records that the Proposed Annora Product infringes both Orange Book Listed Patents and that the claims are valid and enforceable with respect to propranolol-containing products. Annora is permanently enjoined from making, using, selling, offering to sell, importing, or distributing the infringing product in the United States unless specifically authorised under the separately executed Settlement Agreement, which likely contains a negotiated market entry date.
At 754 days, the case ran longer than many Hatch-Waxman disputes that terminate early via voluntary dismissal, suggesting substantive settlement negotiations rather than a rapid capitulation. The existence of a private Settlement Agreement — referenced but not publicly filed — means key commercial terms such as any authorised generic licence or entry date remain undisclosed. The public record does confirm the patents’ validity and enforceability, strengthening Pierre Fabre’s position against any future ANDA challengers for propranolol hemangioma products.
Filing to Consent Judgment in 754 days
754 days — above the median for ANDA Hatch-Waxman disputes in Delaware District Court
Consent judgment and injunction: what the resolution means for both parties
Consent judgment: stronger than a voluntary dismissal
A consent judgment is a court-ordered, judicially enforceable resolution. Unlike a voluntary dismissal, it carries the force of a final judgment. Here, the court retains jurisdiction to enforce compliance, and the judgment expressly records both infringement and patent validity — creating a binding public record that goes beyond what most settlements produce. Pierre Fabre can use this judgment to pursue contempt proceedings if Annora violates the injunction.
Judicially enforceable settlementPatents validated on the record — generic entry blocked
Pierre Fabre secured an on-record concession that US8987262B2 and US8338489B2 are valid, enforceable, and infringed by propranolol-containing ANDA products. This is a materially stronger outcome than a simple dismissal: future ANDA filers cannot easily argue the patents are weak, and the injunction bars Annora from U.S. market entry absent authorisation under the confidential Settlement Agreement. Any licensed entry window is likely defined in that private agreement.
Patents upheld and enforcedAnnora concedes infringement and validity — entry date TBD
Annora Pharma admitted infringement and patent validity in the consent judgment, a significant concession that effectively ends any near-term generic competition absent a negotiated licence. The undisclosed Settlement Agreement may grant Annora a future authorised entry date — a common Hatch-Waxman resolution mechanism — but the public record is silent on this point. Annora faces a permanent injunction in the meantime, and any breach triggers court-supervised enforcement.
Injunction; entry subject to licenceStrengthened exclusivity for propranolol hemangioma franchise
The consent judgment reinforces Orange Book exclusivity for Pierre Fabre’s propranolol hemangioma product. With validity conceded on the public record, subsequent ANDA filers face a heightened evidentiary burden to distinguish or design around these patents. The case also signals the strength of academic co-ownership structures — both a university hospital and a university are named co-patentees alongside the commercial entity, suggesting collaborative research origins that may complicate third-party challenges.
Exclusivity reinforcedFull party and counsel information
| Role | Name | Type | Detail |
|---|---|---|---|
| Plaintiff | Pierre Fabre Medicament SAS | Individual | French pharma group and academic co-patentees — holders of US8987262B2 and US8338489B2Search in Eureka ↗ |
| Co-Plaintiff | Centre Hospitalier Universitaire de Bordeaux | Individual | Search in Eureka ↗ |
| Co-Plaintiff | Pierre Fabre Pharmaceuticals, Inc. | Company | Search in Eureka ↗ |
| Co-Plaintiff | Universite de Bordeaux | Individual | Search in Eureka ↗ |
| Defendant | Annora Pharma Private, Ltd. | Company | Annora Pharma Private Ltd. — Indian generic pharmaceutical manufacturer, ANDA filerSearch in Eureka ↗ |
| Plaintiff counsel | Erin M. Dunston | Attorney | Counsel for Pierre Fabre Medicament SASSearch in Eureka ↗ |
| Plaintiff counsel | John David Simmons | Attorney | Counsel for Pierre Fabre Medicament SASSearch in Eureka ↗ |
| Plaintiff counsel | Keith Aaron Jones | Attorney | Counsel for Pierre Fabre Medicament SASSearch in Eureka ↗ |
| Plaintiff counsel | Phillip L. Hirschhorn | Attorney | Counsel for Pierre Fabre Medicament SASSearch in Eureka ↗ |
| Plaintiff counsel | Travis Bliss | Attorney | Counsel for Pierre Fabre Medicament SASSearch in Eureka ↗ |
| Plaintiff law firm | Panitch Schwarze, Belisario & Nadel LLP | Law Firm | Representing Pierre Fabre Medicament SASSearch in Eureka ↗ |
| Defendant counsel | Alexander V. Alfano | Attorney | Counsel for Annora Pharma Private, Ltd.Search in Eureka ↗ |
| Defendant counsel | Christopher M. Gallo | Attorney | Counsel for Annora Pharma Private, Ltd.Search in Eureka ↗ |
| Defendant counsel | George J. Barry , III | Attorney | Counsel for Annora Pharma Private, Ltd.Search in Eureka ↗ |
| Defendant counsel | Kenneth Laurence Dorsney | Attorney | Counsel for Annora Pharma Private, Ltd.Search in Eureka ↗ |
| Defendant counsel | Michael P. Hogan | Attorney | Counsel for Annora Pharma Private, Ltd.Search in Eureka ↗ |
| Defendant counsel | R. Touhey Myer | Attorney | Counsel for Annora Pharma Private, Ltd.Search in Eureka ↗ |
| Defendant counsel | Richa B. Patel | Attorney | Counsel for Annora Pharma Private, Ltd.Search in Eureka ↗ |
| Defendant counsel | Timothy H. Kratz | Attorney | Counsel for Annora Pharma Private, Ltd.Search in Eureka ↗ |
| Defendant law firm | Kratz & Barry LLP | Law Firm | Representing Annora Pharma Private, Ltd.Search in Eureka ↗ |
| Defendant law firm | Morris James LLP | Law Firm | Representing Annora Pharma Private, Ltd.Search in Eureka ↗ |
| Presiding judge | Judge Jennifer L. Hall | Judge | Delaware District CourtSearch in Eureka ↗ |
Official order — verbatim text
The consent judgment is unusually explicit for a settlement-driven resolution: it records affirmative findings of infringement and patent validity on the public docket rather than simply dismissing claims. This goes beyond procedural housekeeping — it creates a judicially entered record that Pierre Fabre can cite in future ANDA disputes. The dismissal of all claims ‘with prejudice and without costs’ confirms finality for Annora, while the court’s retained jurisdiction over the Settlement Agreement ensures ongoing compliance oversight.
US8987262B2 & US8338489B2 — propranolol beta-blocker hemangioma treatment patents
US8987262B2 (App. No. 13/678,802) and US8338489B2 (App. No. 12/599,266) cover the use of propranolol, a non-selective beta-adrenergic blocker, in the treatment of hemangiomas — typically infantile hemangiomas, which represent the most common benign vascular tumour in infants. The patents derive from collaborative research involving Pierre Fabre Medicament, Université de Bordeaux, and the Centre Hospitalier Universitaire de Bordeaux, reflecting the academic discovery origins of propranolol’s repurposed oncological and vascular application. Both patents are listed in the FDA Orange Book, triggering Hatch-Waxman ANDA litigation rights.
The strategic significance of these patents lies in their position as the primary IP barrier to generic propranolol hemangioma products entering the U.S. market. Propranolol’s use in hemangiomas was a notable therapeutic repurposing — historically used for cardiac conditions, its efficacy in infantile hemangiomas was a relatively recent clinical discovery, making the patents both scientifically novel and commercially valuable. With Annora’s validity concession now on the public record, competing generic manufacturers face a substantially higher practical burden when evaluating Paragraph IV certification strategies against these specific claims.
Should you run an FTO analysis against US8987262B2 and US8338489B2?
Any pharmaceutical company, generic manufacturer, or contract development and manufacturing organisation (CDMO) evaluating a propranolol-based ANDA for hemangioma indications should treat these two Orange Book patents as high-priority FTO targets. The consent judgment’s on-record validity finding means that a Paragraph IV certification path carries elevated litigation risk — and the settlement precedent signals Pierre Fabre’s willingness to enforce aggressively. Product and regulatory teams planning paediatric dermatology or vascular formulations with propranolol as the active ingredient need current claim mapping before ANDA submission.
PatSnap Eureka’s FTO Search Agent allows IP and R&D teams to run automated claim mapping against US8987262B2 and US8338489B2, identify claim scope relative to proposed formulations, and surface relevant prosecution history that may define or limit coverage. Eureka also monitors new ANDA filings and Orange Book patent listings in real time, alerting teams to competitive intelligence signals — such as whether Annora’s ANDA No. 217567 receives a future authorised entry date that might reset market dynamics.
Run a freedom-to-operate analysis on US8987262B2 to assess your product’s exposure
Run FTO in Eureka →Similar Hatch-Waxman ANDA patent cases in Delaware District Court
Explore comparable ANDA infringement disputes involving pharmaceutical formulation patents litigated in Delaware District Court, including propranolol and beta-blocker cases.
What this case signals for the Hatch-Waxman pharmaceutical patent landscape
This consent judgment illustrates the enduring leverage of Orange Book patent listings and the risk generic filers face when challenging branded formulation patents.
Consent judgments create precedent weight that dismissals do not
Unlike a stipulated dismissal, a consent judgment is a public, court-entered record of validity and infringement. Patent holders facing serial ANDA challenges should consider whether negotiating a consent judgment — rather than a simple dismissal — creates stronger deterrence against future filers targeting the same Orange Book patents.
Academic co-patentees add complexity but not necessarily weakness
The inclusion of Université de Bordeaux and Centre Hospitalier Universitaire de Bordeaux as co-plaintiffs reflects publicly funded research origins. Generic challengers sometimes target standing or ownership issues in such structures. Here, the challenge did not succeed on those grounds, suggesting Pierre Fabre had adequately aligned co-owner interests before litigation.
SAS v Annora — key questions answered
The consent judgment entered on 25 November 2024 explicitly found that Annora’s proposed generic propranolol product (ANDA No. 217567) infringes US8987262B2 and US8338489B2, and that both patents are valid and enforceable with respect to propranolol-containing products. Annora was permanently enjoined from U.S. market entry without authorisation under the confidential Settlement Agreement.
A consent judgment is a court-ordered resolution carrying the force of a final judgment, creating an enforceable public record of any agreed findings. A voluntary dismissal typically ends the case without substantive findings. In this case, Pierre Fabre obtained an on-record concession of infringement and validity — a stronger enforcement and deterrence tool than a simple dismissal would have provided.
The two Orange Book-listed patents at issue are US8987262B2 (App. No. 13/678,802) and US8338489B2 (App. No. 12/599,266). Both cover propranolol-based formulations or methods for treating hemangiomas and were asserted against Annora’s ANDA No. 217567 for a generic propranolol product.
The consent judgment binds only the parties to this action — Annora’s validity concession is not legally binding on other ANDA filers. However, it creates a persuasive public record and signals Pierre Fabre’s enforcement posture. Future Paragraph IV challengers should treat this judgment as a practical signal that these patents will be vigorously defended and that the validity arguments Annora may have raised were not sufficient to avoid concession.
The specific commercial terms — including any authorised generic entry date granted to Annora — are contained in a private Settlement Agreement that has not been made public. The court record confirms only that an injunction is in place and that any market entry by Annora is conditional on specific authorisation under that agreement. Monitoring FDA Orange Book listings and any 180-day exclusivity triggers for ANDA No. 217567 may provide indirect signals about the agreed entry timeline.
PatSnap Eureka searches patents and litigation data to answer instantly.